Finanzen von Alkermes Plc (ALKS)ALKSAlkermes Plc

Alkermes Plc (ALKS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is VIVITROL, accounting for 25.1% of total sales, equivalent to $124.45M. Other significant revenue streams include ARISTADA and LUMRYZ. Understanding this composition is critical for investors evaluating how ALKS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Alkermes Plc maintains a gross margin of 75.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.03%, while the net margin is 0.10%. These profitability ratios, combined with a Return on Equity (ROE) of 3.85%, provide a clear picture of how effectively ALKS converts its operational activities into shareholder value.

In the context of the broader market, ALKS competes directly with industry leaders such as PRAX and AMRX. With a market capitalization of $6.80B, it holds a significant position in the sector. When comparing efficiency, ALKS's gross margin of 75.67% stands against PRAX's N/A and AMRX's 42.01%. Such benchmarking helps identify whether Alkermes Plc is trading at a premium or discount relative to its financial performance.

Alkermes has shown robust financial performance with a total revenue of $888.9 million for the first half of 2026, a 27.5% increase from the previous year. The gross margin is currently at 75.67%, indicating strong profitability, although it has decreased from previous quarters. The company has also demonstrated a significant year-to-date stock price increase of 45.86%.